COVID-19 Research

Exclusive global rights for Commercialization

PlantEXT has entered into a license agreement with The Government of the State of Israel and has funded research at ARO thus acquiring the exclusive global rights to commercialize ARO’s intellectual property (“IP”) and products based on formulations of active cannabis compounds and possibly other pharmaceutical drugs as a basis for development of products for the treatment of lung inflammation such as the inflammation provoked by COVID-19. (pending final government approval)

Preliminary Research Results

Preliminary research results have identified cannabis fractions and compounds that cause anti-inflammatory activity in lung epithelial cell line and macrophages in 2D in vitro cultures using different associated markers, those associated with COVID inflammation and those characterize asthma inflammation.

Scientifically Tested
Early mover advantage to fight COVID 19 lung inflammation
Potential formulation for cannabis-based API

Get In Touch

We would love to hear from you. We are looking for partners to join our mission.

Learn More